

Partner Organisations:

Health Research Authority, England
 NHS Research Scotland
 HSC Research & Development, Public Health Agency, Northern Ireland

NIHR Clinical Research Network, England
 NISCHR Permissions Co-ordinating Unit, Wales

Notification of Non-Substantial/Minor Amendments(s) for NHS Studies

This template **must only** be used to notify NHS/HSC R&D office(s) of amendments, which are **NOT** categorised as Substantial Amendments.

If you need to notify a Substantial Amendment to your study then you MUST use the appropriate Substantial Amendment form in IRAS.

Instructions for using this template

- For guidance on amendments refer to <http://www.hra.nhs.uk/research-community/during-your-research-project/amendments/>
- This template should be completed by the CI and optionally authorised by Sponsor, if required by sponsor guidelines.
- This form should be submitted according to the instructions provided for NHS/HSC R&D at <http://www.hra.nhs.uk/research-community/during-your-research-project/amendments/which-review-bodies-need-to-approve-or-be-notified-of-which-types-of-amendments/> . If you do not submit your notification in accordance with these instructions then processing of your submission may be significantly delayed.

1. Study Information

Full title of study:	A Randomised Controlled Trial to Investigate the Effectiveness of Thoracic Epidural Blockade and Paravertebral Blockade in Reducing Chronic Post-Thoracotomy Pain (TOPIC2)
IRAS Project ID:	248427
Sponsor Amendment Notification number:	Non-Substantial Amendment 2
Sponsor Amendment Notification date:	30-Jan-2019
Details of Chief Investigator:	
Name [first name and surname]	Professor Fang Gao Smith
Address:	University of Birmingham
Postcode:	B15 2TT
Contact telephone number:	0121 371 3243
Email address:	f.gaosmith@bham.ac.uk
Details of Lead Sponsor:	
Name:	University of Birmingham
Contact email address:	Topic2@trials.bham.ac.uk
Details of Lead Nation:	
Name of lead nation <i>delete as appropriate</i>	England
If England led is the study going through CSP? <i>delete as appropriate</i>	Yes
Name of lead R&D office:	Birmingham Heartlands Hospital

Partner Organisations:

Health Research Authority, England
 NHS Research Scotland
 HSC Research & Development, Public Health Agency, Northern Ireland
 NIHR Clinical Research Network, England
 NISCHR Permissions Co-ordinating Unit, Wales

2. Summary of amendment(s)

This template must only be used to notify NHS/HSC R&D office(s) of amendments, which are **NOT** categorised as Substantial Amendments.
 If you need to notify a **Substantial Amendment to your study then you MUST use the appropriate Substantial Amendment form in IRAS.**

No.	Brief description of amendment <i>(please enter each separate amendment in a new row)</i>	Amendment applies to <i>(delete/ list as appropriate)</i>		List relevant supporting document(s), including version numbers <i>(please ensure all referenced supporting documents are submitted with this form)</i>		R&D category of amendment <i>(category A, B, C) For office use only</i>
		Nation	Sites	Document	Version	
1	Addition of Site: James Cook University Hospital, Marton Road, Middlesbrough, TS4 3BW. Principal Investigator: Dr Mindaugas Balciunas	England	James Cook University Hospital	N/A	N/A	

Partner Organisations:

Health Research Authority, England
NHS Research Scotland
HSC Research & Development, Public Health Agency, Northern Ireland

NIHR Clinical Research Network, England
NISCHR Permissions Co-ordinating Unit, Wales

3. Declaration(s)

Declaration by Chief Investigator

- I confirm that the information in this form is accurate to the best of my knowledge and I take full responsibility for it.
- I consider that it would be reasonable for the proposed amendment(s) to be implemented.

Signature of Chief Investigator: Fang Gao

Print name: FANG GAO

Date: 01/Feb/2019

Optional Declaration by the Sponsor's Representative (as per Sponsor Guidelines)

The sponsor of an approved study is responsible for all amendments made during its conduct.

The person authorising the declaration should be authorised to do so. There is no requirement for a particular level of seniority; the sponsor's rules on delegated authority should be adhered to.

- I confirm the sponsor's support for the amendment(s) in this notification.

Signature of sponsor's representative: Susan Tebbs

Print name: SUSAN TEBBS

Post: DEPUTY DIRECTOR, BCU

Organisation: Birmingham Clinical Trials Unit [BCU]
at the University of Birmingham

Date: 04 Feb 2019